Cue Biopharma, Inc. Human Resources Contracts & Agreements
27 Contracts & Agreements
- Bonus & Incentive Agreements (9 contracts)
- Compensation Agreements (4)
- Consulting Agreements (3)
- Employment Agreements (11)
- Director Compensation Policy effective June 5, 2024 (Filed With SEC on November 14, 2024)
- Form of stock option award under 2016 Non-Employee Equity Incentive Plan (Filed With SEC on August 14, 2024)
- Form of stock option award under 2016 Omnibus Incentive Plan (Filed With SEC on August 14, 2024)
- Director Compensation Policy effective December 7, 2023 (Filed With SEC on March 28, 2024)
- Amendment No. 1 to Consulting Agreement between Cue Biopharma, Inc. and Peter A. Kiener, dated September 1, 2023 (Filed With SEC on November 3, 2023)
- Consulting Agreement effective June 7, 2023 entered into between Cue Biopharma, Inc. and Peter A Kiener, D.Phil (Filed With SEC on August 8, 2023)
- Amendment No. 1 to Cue Biopharma, Inc. 2016 Non-Employee Equity Incentive Plan (Filed With SEC on August 8, 2023)
- Amendment No. 2 to Cue Biopharma, Inc. 2016 Omnibus Incentive Plan (Filed With SEC on August 8, 2023)
- Director Compensation Policy dated January 1, 2021 (Filed With SEC on May 10, 2022)
- Consulting Agreement, dated January 1, 2017, between the Registrant and Ken Pienta, as amended by Amendment No. 1 to Consulting Agreement dated December 15, 2021 (Filed With SEC on March 16, 2022)
- Third Amended and Restated Executive Employment Agreement dated March 4, 2021 between the Company and Daniel Passeri (Filed With SEC on March 9, 2021)
- Executive Employment Agreement dated August 21, 2020 between the Company and Kerri-Ann Millar (Filed With SEC on August 24, 2020)
- Amendment No. 1 to Cue Biopharma, Inc. 2016 Omnibus Incentive Plan (Filed With SEC on March 12, 2020)
- Second Amended and Restated Executive Employment Agreement dated February 10, 2020 between the Company and Daniel Passeri (Filed With SEC on February 10, 2020)
- Amended and Restated Executive Employment Agreement dated October 3, 2019 between the Company and Daniel Passeri (Filed With SEC on October 7, 2019)
- Amended and Restated Executive Employment Agreement dated October 3, 2019 between the Company and Anish Suri (Filed With SEC on October 7, 2019)
- Director Compensation Policy dated October 30, 2018 (Filed With SEC on March 14, 2019)
- Executive Employment Agreement between the Registrant and Bethany Mancilla dated as of June 22, 2018 (Filed With SEC on August 13, 2018)
- Executive Employment Agreement between the Registrant and Anish Suri dated as of April, 2018 (Filed With SEC on August 13, 2018)
- Executive Employment Agreement between the Registrant and Colin G. Sandercock dated as of November 15, 2017 (Filed With SEC on December 5, 2017)
- Form of stock option award under 2016 Non-Employee Equity Incentive Plan (Filed With SEC on September 21, 2017)
- Cue Biopharma, Inc. 2016 Non-Employee Equity Incentive Plan (Filed With SEC on September 21, 2017)
- Form of stock option award under 2016 Omnibus Incentive Plan (Filed With SEC on September 21, 2017)
- Cue Biopharma, Inc. 2016 Omnibus Incentive Plan, as amended and restated (Filed With SEC on September 21, 2017)
- Employment Agreement between the Registrant and Daniel R. Passeri dated August 29, 2016 (Filed With SEC on September 21, 2017)
- Executive Employment Agreement between the Registrant and Ronald D. Seidel dated effective June 15, 2015 (Filed With SEC on September 21, 2017)
- Executive Employment Agreement between the Registrant and Rodolfo J. Chaparro dated effective June 15, 2015 (Filed With SEC on September 21, 2017)
